Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows

Lynparza Particularly Effective in Prostate Cancer Patients Carrying BRCA Mutations, Phase 2 Study Shows
Lynparza (olaparib), a breast and ovarian cancer treatment, is also showing promising results in men with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in DNA repair genes, particularly the BRCA1 and BRCA2 genes, according to data from a Phase 2 study. The study’s final data, “Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial,” was published in the journal The Lancet Oncology. Lynparza is an oral treatment developed by AstraZeneca and Merck (known as MSD outside the U.S. and Canada), which has been approved to treat advanced forms of ovarian and breast cancer. As a PARP inhibitor, Lynparza works by blocking the activity of the PARP enzyme — a DNA damage sensor — leading to the accumulation of DNA damage and ultimately the death of cancer cells. This therapy is particularly effective in can
Subscribe or to access all post and page content.